New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
08:22 EDTNVAXNovavax's experimental vaccine against new virus shows positive results
Novavax and The University of Maryland School of Medicine announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus blocked infection in laboratory studies. UM SOM and Novavax also reported that a vaccine candidate against Severe Acute Respiratory Syndrome Coronavirus developed by Novavax on a similar platform also inhibited virus infection. This peer-reviewed manuscript describes a novel method to rapidly develop vaccines against previously unknown viruses, such as MERS-CoV, which appear suddenly and cause severe illnesses in humans.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 29, 2015
14:16 EDTNVAXNovavax presents new data from non-human primate Ebola challenge
Novavax announced Gale Smith, Ph.D., VP, Vaccine Development, will present, "Recombinant EBOV/Makona Glycoprotein Nanoparticle Vaccine Produced in Sf9 Insect Cells," at the 7th International Symposium on Filoviruses, Saturday, March 28,at 10:15 a.m. at the Washington Marriott Metro Center in Washington, D.C. As part of his talk, Dr. Smith will present new data from a second non-human primate study which was conducted by the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases. In that study, animals received two injections of a 5g dose of Novavax' Ebola GP Vaccine together with its proprietary Matrix-M adjuvant and were then challenged with a lethal dose of the Ebola virus. Similar to the previous NHP study, the challenge was lethal for the control animals, whereas the animals immunized with Novavax' EBOV GP Vaccine remain healthy 18 days post challenge. "This data provides significant, independent confirmation that our Ebola GP Vaccine is safe and effective in providing protection in NHP models," said Dr. Smith. "Our vaccine is the first subunit Ebola GP-based vaccine to provide protection in non-human primates and this confirmatory data strongly supports the advancement of this program. Importantly, although we developed our Ebola GP Vaccine from the Makona strain, which is the strain responsible for the recent Ebola epidemic in West Africa, these primates were challenged with the Kikwit strain of Ebola, which suggests that our vaccine candidate may be protective across different variants of the virus." Novavax is currently conducting a Phase 1 clinical trial of its Ebola GP Vaccine in healthy subjects. It expects top-line data from this trial in mid-2015.
March 27, 2015
06:08 EDTNVAXNovavax assumed with a Buy at Citigroup
Subscribe for More Information
March 26, 2015
09:23 EDTNVAXOn The Fly: Pre-market Movers
Subscribe for More Information
March 25, 2015
20:11 EDTNVAXNovavax 24.14M share Secondary priced at $7.25
Subscribe for More Information
March 24, 2015
19:40 EDTNVAXOn The Fly: After Hours Movers
Subscribe for More Information
16:02 EDTNVAXNovavax files to sell $175M in common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use